Autonomix Medical, Inc. (AMIX)
| Market Cap | 57.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 18.81M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,809 |
| Open | 3.200 |
| Previous Close | 3.260 |
| Day's Range | 3.010 - 3.255 |
| 52-Week Range | 2.500 - 7.600 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2024 |
About AMIX
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company also has an agreement with NoiseFigure Research, Inc. to develop next generation of its proprietary microchip. Autonomix Medical, Inc. was incorporated in 2014 and is based in The Woodlands, Texas. [Read more]
Financial Performance
Financial StatementsNews
Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Wednesday, May 1 st at 3:20 PM ET THE WOODLANDS, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company ...
Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
Patent portfolio with over 100 patents, issued and pending, protects technology targeting a $100 billion market opportunity
Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation
Preclinical study demonstrates potential of Autonomix technology to make renal denervation safer and more effective
Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker
Live webcast with members of the Autonomix management team, on Thursday, April 11 th at 12:00 PM ET
Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast presentation on Thursday, April 4 th at 3:55 PM ET THE WOODLANDS, TX, March 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical d...
Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024
Live webcast presentation on Wednesday, March 20 th at 11:50 AM ET THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medica...
Autonomix Appoints Jennifer Cook as Chief Business Officer
Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands
Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer
Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity
Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29 th at 12:00 PM ET
Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer
Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate radiofre...
Autonomix Medical, Inc. (NASDAQ:AMIX) to Present at Integrous Big Hearts, Big Ideas Virtual Investor Conference
Webcast presentation on Wednesday, February 14th at 10:30 AM EST THE WOODLANDS, TX / ACCESSWIRE / February 9, 2024 / Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical dev...
Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain
First study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event
Live moderated webcast with members of the Autonomix management team on Wednesday, February 7 th at 10:00 AM ET
Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024
THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to re...
Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix's development and strategic opportunities THE WOODLANDS, TX, J...
Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix's development and strategic opportunities THE WOODLANDS, TX, J...
Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market THE WOODLANDS, TX., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Auto...
Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “C...